



30  
31 <sup>14</sup>Burke Neurological Institute, Weill Cornell Medicine, White Plains, New York, United States  
32 of America

33

34 \*Corresponding author

35 E-mail: [howardfeldman@health.ucsd.edu](mailto:howardfeldman@health.ucsd.edu) (HF)

36

37 ¶These authors contributed equally to this work.

38 ^Membership of the ADCS BenfoTeam Study Group is provided in the Acknowledgements.

## 39 **Abstract**

40 **Background:** Benfotiamine provides an important novel therapeutic direction in Alzheimer's  
41 disease (AD) with possible additive or synergistic effects to amyloid targeting therapeutic  
42 approaches.

43 **Objective:** To conduct a seamless phase 2A-2B proof of concept trial investigating tolerability,  
44 safety, and efficacy of benfotiamine, a prodrug of thiamine, as a first-in-class small molecule  
45 oral treatment for early AD.

46 **Methods:** This is the protocol for a randomized, double-blind, placebo-controlled 72-week  
47 clinical trial of benfotiamine in 406 participants with early AD. Phase 2A determines the highest  
48 safe and well-tolerated dose of benfotiamine to be carried forward to phase 2B. During phase  
49 2A, real-time monitoring of pre-defined safety stopping criteria in the first approximately 150  
50 enrollees will help determine which dose (600 mg or 1200 mg) will be carried forward into phase  
51 2B. The phase 2A primary analysis will test whether the rate of tolerability events (TEs) is  
52 unacceptably high in the high-dose arm compared to placebo. The primary safety endpoint in  
53 phase 2A is the rate of TEs compared between active and placebo arms, at each dose. The  
54 completion of phase 2A will seamlessly transition to phase 2B without pausing or stopping the  
55 trial. Phase 2B will assess efficacy and longer-term safety of benfotiamine in a larger group of

56 participants through 72 weeks of treatment, at the selected dose. The co-primary efficacy  
57 endpoints in phase 2B are CDR-Sum of Boxes and ADAS-Cog13. Secondary endpoints include  
58 safety and tolerability measures; pharmacokinetic measures of thiamine and its esters,  
59 erythrocyte transketolase activity as blood markers of efficacy of drug delivery; ADCS-ADL-  
60 MCI; and MoCA.

61 **Conclusion:** The BenfoTeam trial utilizes an innovative seamless phase 2A-2B design to  
62 achieve proof of concept. It includes an adaptive dose decision rule, thus optimizing exposure to  
63 the highest and best-tolerated dose.

64 **Trial Registration:** ClinicalTrials.gov identifier: NCT06223360, registered on January 25,  
65 2024.

## 66 Introduction

67 Alzheimer's disease (AD) is a progressive age-associated neurodegenerative disease. It  
68 is the most common cause of dementia and has devastating socioeconomic implications. More  
69 than 5 million people are afflicted with AD and related dementias in the United States, and by  
70 2050 this number could rise as high as 16 million, with annual costs of over \$1 trillion [1]. The  
71 potential to preserve, or even improve, cognition in adults at high risk of cognitive decline due to  
72 AD clearly has important implications, not only for the affected individual, but also for the  
73 support system that bears the social and financial burdens of long-term caregiving. Despite  
74 recent advances in amyloid targeting therapies, they do not address processes that are upstream  
75 and downstream of the amyloid cascade. Thus, complementary therapies that address these  
76 processes are needed.

77 Benfotiamine a prodrug of thiamine provides a novel therapeutic direction in AD that has  
78 potential for additive or synergistic effects beyond current mainstream approaches. It is a first-in-  
79 class small molecule with a unique mechanism of action, that raises blood thiamine (vitamin B1)  
80 50-100 times to pharmacological levels. In this way, it addresses and treats a well-characterized  
81 tissue thiamine action deficiency in AD that is associated with changes in glucose metabolism  
82 and thiamine dependent post-translational modifications that are linked to AD pathology. This  
83 includes action on the  $\alpha$ -Ketoglutarate Dehydrogenase Complex (KGDHC)-regulated  
84 succinylation of the TCA cycle that links brain glucose metabolism to AD pathophysiology [2].  
85 These related post translational modifications have been identified on tau and Abeta with effects  
86 that have been shown to promote plaque and tangle formation [3], neuroinflammation [4, 5],  
87 neurodegeneration [2], and increased advanced glycation end products (AGE) [6] which are  
88 regulated by thiamine. AGE are toxic modifications that form by the chemical addition of  
89 glucose and its byproducts to proteins, lipids and nucleotides when glucose is not tightly  
90 controlled in the cell, as is seen with the abnormal glucose metabolism in AD. High  
91 concentrations of AGE are predictive of long-term decline in cognition-related daily living  
92 performance in patients with AD [7]. Whereas thiamine deficiency increases AGE, increasing  
93 brain thiamine activates transketolase, which diminishes AGE [8, 9].

94 CNS thiamine deficiency and its effects on memory and cognition have been well known  
95 since 1930s [10]. It is the cause of the amnesic disorder of the Wernicke-Korsakoff syndrome  
96 [10] with data strongly supporting its pathogenetic role as well in AD. Thiamine dependent  
97 processes are deficient in autopsied brains from AD patients including transketolase (controls the  
98 pentose phosphate pathway), the pyruvate dehydrogenase complex [PDHC, links glycolysis to  
99 the tricarboxylic acid cycle (TCA)], glyoxalase (detoxification of AGE precursors) and KGDHC

100 (controls the TCA cycle) [11, 12]. Furthermore, the reduced thiamine dependent enzyme activity  
101 measured in post-mortem brain tissue in AD patients, correlates with pre-mortem degree of  
102 impairment on the Clinical Dementia Rating (CDR) score [13]. Preclinical studies using a range  
103 of models including isolated proteins, cell systems and animal models demonstrate that thiamine  
104 deficiency stimulates many AD-like pathological changes including amyloid plaque and tangle  
105 formation, neuronal loss, inflammation, oxidative stress, cholinergic deficits, abnormally reduced  
106 glucose metabolism and memory deficits [14].

107         Recent data provides a mechanistic framework for the decline in thiamine-dependent  
108 processes in the brains of patients with AD. Thiamine entry into the brain is controlled by  
109 transporters and the transporters are diminished in autopsied brains from AD patients and in  
110 brains from mouse models of AD [15]. High concentrations of thiamine in the serum such as  
111 those induced by benfotiamine can overcome a reduction in transporters [16]. Model systems  
112 studies have demonstrated that high thiamine achieved by increasing dosages of benfotiamine  
113 reverses AD-like changes including restoring thiamine-dependent enzymes, with improvement in  
114 brain glucose metabolism, in reducing plaques [17] and tangles [3], neuroinflammation [4, 5]  
115 neurodegeneration [2], and reducing AGE [6].

116         These preclinical studies have supported a small, single-site 12-month pilot trial of  
117 benfotiamine in persons with early AD (35 per treatment arm) that demonstrated benfotiamine is  
118 safe and well tolerated with encouraging PK and PD responses [6]. The treatment delivery of  
119 benfotiamine in a dose of 600 mg/d achieved its intended PK outcome with a 161-fold mean  
120 increase in blood thiamine. The trial also provided preliminary evidence of efficacy of  
121 benfotiamine on cognitive and functional outcomes. While group difference in change on the  
122 Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog) did not reach statistical

123 significance, there was a numerical benefit, with 43% less decline in benfotiamine (-1.39) vs  
124 placebo (-3.26) (mixed effect model  $p = 0.071$ , GEE  $p = 0.137$ , and non-parametric Wilcoxon  
125 rank sum test  $p = 0.098$ ). The CDR, a composite of cognition and everyday function, showed a  
126 significant benefit ( $p=0.034$ ), and other measures showed favorable treatment effects on patterns  
127 of brain glucose utilization ( $p=0.002$ ) and patterning scores ( $p=0.0329$ ) on  $^{18}\text{F}$ -  
128 fluorodeoxyglucose positron-emission tomography (FDG PET). Plasma AGE, marking  
129 pharmacodynamic target engagement, were also reduced in a randomly selected subset of  
130 patients ( $p=0.044$ ) [6]. In this study there was a pattern of pharmacogenomic response where  
131 participants without *APOE*  $\epsilon 4$  were more responsive to benfotiamine than those with *APOE*  $\epsilon 4$ .

132         These preliminary results justify the testing of benfotiamine in a larger seamless phase  
133 2A-phase 2B randomized controlled trial (RCT) to investigate its safety, tolerability, and efficacy  
134 in early AD [18]. The BenfoTeam trial will provide the next level of necessary clinical, safety  
135 and efficacy evidence to establish “Proof of Concept” (POC) for benfotiamine.

## 136 **Materials and methods**

### 137 **Objectives**

138         The primary objective of phase 2A is to determine the highest safe and well-tolerated  
139 daily dose of benfotiamine (600 mg/d or 1200 mg/d), as evaluated by the rate of tolerability  
140 events (TEs), to advance to the longer-term phase 2B study. The secondary objective of phase  
141 2A is to evaluate additional measures of safety and tolerability of 600 mg/d or 1200 mg/d doses  
142 of benfotiamine.

143         The primary objective of phase 2B is to assess the efficacy of benfotiamine on global  
144 function and cognition over 72 weeks. The secondary objectives of phase 2B are to evaluate: 1)

145 longer-term safety and tolerability of benfotiamine treatment, 2) the effects of benfotiamine's PK  
146 relationships to primary clinical outcome measures, (plasma thiamine, and thiamine esters in  
147 whole blood, thiamine diphosphate (ThDP) and thiamine monophosphate (ThMP) and  
148 erythrocyte transketolase activity), and 3) benefits of benfotiamine on everyday activities of  
149 daily living and specific aspects of cognitive function (e.g., memory) over 72 weeks.

150 Exploratory objectives of phase 2B are to evaluate: 1) the downstream biological effects  
151 of treatment with benfotiamine on measures of neurodegeneration (cortical thickness MRI,  
152 plasma neurofilament light chain, total tau), neuroinflammation (plasma glial fibrillary acid  
153 protein) and AD pathophysiology (plasma p-tau231, p-tau217, A $\beta$  42/40, p-tau217/np-tau217(p-  
154 tau217 ratio) over 72 weeks, 2) the effects of benfotiamine on neuropsychiatric symptoms and  
155 cognitive-functional composite measures, 3) the effects of benfotiamine on remotely-  
156 administered measures of cognition, and to compare the sensitivity of remote and in-person  
157 cognitive assessments, and 4) the relationship between PK measures, including plasma thiamine,  
158 thiamine esters in whole blood (ThDP and ThMP), erythrocyte transketolase activity, and PD  
159 measures including AGE.

## 160 **Design**

161 This overall design is a placebo controlled parallel group RCT over 72 weeks. The Phase  
162 2A safety and dose selection decision will be reached when either 21 total TEs have been  
163 observed across both the high dose arm and the placebo arm, or when 160 person-months of  
164 exposure have accumulated in each of the high dose and placebo arms, whichever comes first  
165 (see S1 File). If the tolerability stopping rule is not reached by this predetermined number of  
166 TEs, the 1200 mg dose will continue, the 600 mg dose will be titrated upwards, and  
167 randomization will be adjusted for the remainder of trial enrollment to be 1:1 active versus

168 placebo across the trial population. The completion of phase 2A will seamlessly transition to  
169 phase 2B without pausing or stopping the trial. Phase 2B will assess efficacy and longer-term  
170 safety of benfotiamine at the selected dose in a larger group of participants through 72 weeks of  
171 treatment.

172 The schedule of enrollment, interventions, and assessments is shown in Fig 1. The study  
173 schematic is shown in Fig 2.

174 **Figure 1. Schedule of enrollment, interventions, and assessments**

175

176 **Figure 2. Study schematic**

177

## 178 **Participants**

179 This trial (NCT06223360) will include 406 participants with early AD, including  
180 participants with MCI or mild dementia due to AD according to NIA-AA Diagnostic Criteria  
181 with a positive plasma AD biomarker test result (C<sub>2</sub>N PrecivityAD2; APS2 value >47.5) [19-22].  
182 Key inclusion criteria include aged 50-89, Mini-Mental State Examination (MMSE) total score  
183 20-30, Montreal Cognitive Assessment (MoCA) <26, and CDR score of 0.5 or 1 with memory  
184 score of  $\geq 0.5$  at screening. A complete list of inclusion criteria is presented in Table 1. Key  
185 exclusion criteria include any significant neurological or neurodegenerative disorder (other than  
186 AD), uncontrolled depression or major depression, a current diagnosis of uncontrolled type I or  
187 type II diabetes mellitus, a diagnosis of cancer (unless no evidence of recurrence for 5 years),  
188 any other major psychiatric disorder or active medical condition that impairs cognition or  
189 impacts participation, MRI at screening shows evidence of infection, tumor, cortical infarction,  
190 or multiple lacunes in prefrontal or critical memory regions, and initiation of a monoclonal  
191 antibody treatment targeting brain amyloid (including lecanemab, aducanumab, solanezumab,



192 donanemab) within 6 months. A list of exclusion criteria is presented in Table 2. Recruitment  
 193 and enrollment of participants will occur through the Alzheimer’s Disease Cooperative Study  
 194 (ADCS) network at approximately 50 sites in the United States. A list of participating sites can  
 195 be viewed at [www.clinicaltrials.gov](http://www.clinicaltrials.gov).

196 **Table 1. Inclusion criteria**

Inclusion criteria	
1.	Aged 50 to 89 (inclusive) at screening.
2.	Mild Cognitive Impairment due to AD or Mild probable AD (NIA-AA <sup>1,2</sup> ).
3.	Mini-Mental State Examination (MMSE) score 20-30 inclusive at screening.
4.	Montreal Cognitive Assessment score (MoCA) < 26 at screening.
5.	Clinical Dementia Rating (CDR) global score of 0.5 or 1 with memory score of ≥ 0.5 at screening.
6.	Positive plasma AD biomarker signature: <ol style="list-style-type: none"> <li>a. Plasma test (C<sub>2</sub>N PrecivityAD2). To qualify participants will have a High Amyloid Probability Score (APS2 &gt;47.5).</li> <li>b. If previously treated with any anti-amyloid monoclonal antibody (AAMA) and C<sub>2</sub>N PrecivityAD2 is negative, documentation of a pre-AAMA treatment positive amyloid status with either amyloid PET, CSF, or appropriate plasma test.</li> </ol>
7.	Stable dosage of AchEIs and/or memantine for at least 3 months prior to screening.
8.	Availability of a study partner who has frequent interaction with the participant (approximately >3-4 times per week) and is available for all study visits.
9.	For FDA-approved monoclonal antibodies targeting brain amyloid (including lecanemab, aducanumab, solanezumab, donanemab), participants must be on stable dose of treatment for at least 6 months prior to screening.
10.	Women must be post-menopausal for at least one year or surgically sterile (bilateral tubal ligation, hysterectomy, or bilateral oophorectomy) for at least 6 months prior to screening.
11.	Fluent in English or Spanish.
12.	Living in the community (includes assisted living facilities).
13.	Ambulatory, or able to walk with an assistive device.
14.	Informed consent from the participant (or the participant's legally authorized representative if lacking decisional capacity), as well as study partner consent.

197  
 198 **Note.** <sup>1</sup> Albert, M.S., et al., The diagnosis of mild cognitive impairment due to Alzheimer's disease:  
 199 recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic  
 200 guidelines for Alzheimer's disease. *Alzheimers Dement*, 2011. 7(3): p. 270-9. <sup>2</sup> McKhann, G.M., et al., The  
 201 diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-  
 202 Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease. *Alzheimer's & Dementia*,  
 203 2011. 7(3): p. 263-269.  
 204

205 **Table 2. Exclusion criteria**

Exclusion Criteria	
1.	Significant neurological disorder other than AD including hypoxia, stroke, traumatic brain injury.
2.	Diagnosis of uncontrolled depression or major depression, as determined by DSM-IV, unless successfully treated.
3.	Any other major psychiatric disorder that impairs cognition or impacts participation in the study is exclusionary. Participants with major psychiatric disorders (e.g., severe generalized anxiety disorder, bipolar disorder, schizophrenia etc.) where the condition is felt to be the most significant contributor to the cognitive impairment should be excluded.
4.	Active medical conditions that impair cognition or impact participation in the study, other than AD should be exclusionary. Participants with medical conditions (e.g., severe obstructive sleep apnea) in whom the condition is felt to be the most significant contributor to the cognitive impairment should be excluded.
5.	Significant neurodegenerative diseases, other than AD, and other causes of dementias.
6.	A current diagnosis of uncontrolled type I or type II diabetes mellitus, as defined by Hemoglobin A1 C (Hb A1C > 8).
7.	A current active, uncontrolled seizure disorder.
8.	Participation in another clinical trial for an investigational agent of: <ul style="list-style-type: none"> <li>a. Symptomatic medications, participation is excluded within 4 weeks prior to the screening visit.</li> <li>b. Disease-modifying medications, participation is excluded within 6 months of the screening visit.</li> </ul>
9.	Previous exposure to benfotiamine within past 3 months.
10.	Current serious or unstable medical illness that could interfere with the interpretation of safety and assessment of efficacy in this study.
11.	Diagnosis or treatment of cancer within the past 5 years.
12.	History of alcoholism or substance abuse, current or within past 5 years.
13.	Contraindication to MRI.
14.	MRI at screening showing evidence of infection, tumor, cortical infarction, or multiple lacunes in prefrontal or critical memory regions.
15.	Initiation of an FDA-approved monoclonal antibody treatment targeting brain amyloid (including lecanemab, aducanumab, solanezumab, donanemab) within 6 months prior to the screening visit.
16.	A disability that may prevent the patient from completing all study requirements in the opinion of the PI.

206

207 **Concomitant medications**

208 Use of the following medications is prohibited throughout participation in the study:

209 thiamine or benfotiamine supplements outside of a multivitamin, immunosuppressive

210 medications, chemotherapeutic agents for malignancy, or any concomitant treatment which may  
211 impair cognitive function. Medications that are central nervous system active (e.g., hypnotics)  
212 and may affect cognitive function are not permitted for 72 hours prior to neuropsychological  
213 testing.

214 Eligible participants being treated with FDA-approved acetylcholinesterase inhibitors  
215 (AChEI) and/or memantine at the time of screening are expected to remain on a stable dosage  
216 regimen of these medications for the duration of the trial. They may be initiated as clinically  
217 indicated during the study when a participant is not already on these medications at the outset,  
218 with appropriate documentation. FDA-approved monoclonal antibodies targeting brain amyloid  
219 are permitted, but participants must be stable for at least 6 months on such treatment prior to  
220 screening. For medications not intended to treat AD, participants must be on a stable dose for at  
221 least 4 weeks prior to baseline, except for medications which are administered for a short course  
222 of treatment.

## 223 **Interventions**

224 Benfotiamine capsules, 300 mg, 600 mg, or placebo are provided as opaque dark green  
225 (chlorophyll) colored capsules for oral administration. The placebo group will receive capsules  
226 with microcrystalline cellulose, with all other components, shape, and color identical to the  
227 active treatment. Participants are assigned capsules twice a day (BID; once in the morning and  
228 once in the evening). Participants receive a new supply for each dosing period between study  
229 visits and are provided a diary to track daily intake and timing of dose. During study visits,  
230 participant drug supply will be assessed for compliance.

## 231 **Randomization and blinding**

232 A randomization schedule will be generated and incorporated into an electronic  
233 Randomization and Trial Supplies Management (RTSM) system. The treatment group will be  
234 assigned as the site randomizes the participant. In phase 2A of the trial, as shown in Figure 2,  
235 each participant will be randomly allocated in a 1:1:1 ratio into one of the 3 groups: 1200 mg/day  
236 benfotiamine, 600 mg/day benfotiamine or placebo. At the dose decision point that ends phase  
237 2A, all participants enrolled in the two phase 2A active dose arms will receive a new supply of  
238 benfotiamine at the selected highest tolerable dose for phase 2B. An unscheduled visit at the start  
239 of phase 2B may be required to replace investigational product (IP) supply in all active  
240 participants once the phase 2A dose selection is made. Newly enrolled participants will be  
241 randomized 1:2 active arm to placebo arm until parity is achieved between numbers of active and  
242 placebo arm participants (approximately 150 participants total), randomized 1:1 thereafter  
243 (approximately 100 participants). In both phases of the trial, the randomization will be stratified  
244 by site.

245 Participants and study personnel will be blinded to both treatment arm and dosage. There  
246 will be provisions for the site Principal Investigator (PI) to unblind treatment assignment in  
247 consultation with the ADCS Medical Monitor only in the case of an emergency.

## 248 **Adverse events**

249 All AEs (i.e., a new event or an exacerbation of a pre-existing condition in its frequency  
250 or severity) that occur from the time of consent and up to 30 days after the IP has been  
251 discontinued will be recorded. A treatment emergent AE (TEAE) is defined as any AE that  
252 developed, worsened, or became serious after first dose of IP and prior to 30 days after the last  
253 dose of IP. A serious adverse event (SAE) is an AE that results in any of the following outcomes:  
254 death, life-threatening situation (participant is at immediate risk of death), inpatient

255 hospitalization or prolongation of existing hospitalization, persistent or significant  
256 disability/incapacity, congenital anomaly/birth defect in the offspring of a patient who received  
257 IP, or considered significant by the investigator for any other reason. All AEs will be followed  
258 until resolution or until the Investigator and/or the Medical Monitor determine the event is  
259 chronic or clinically stable.

## 260 **Safety Surveillance**

261 During both phases of the trial, safety surveillance includes monitoring of 1)  
262 AEs/TEAEs/SAEs summarized by grade, attribution, and body systems, by number of events,  
263 and by participant, 2) physical exam abnormalities, 3) vital signs (weight, blood pressure, pulse  
264 rate, temperature, respiration rate), 4) standard 12-lead resting ECG measures, and 4) summaries  
265 of safety laboratory tests.

## 266 **Outcomes**

### 267 **Phase 2A primary endpoints**

268 The primary safety endpoint in phase 2A is the rate of TEs in active and placebo arms at  
269 each dose. A TE is defined as early discontinuation of the IP due to intolerability or a post-  
270 randomization moderate or severe AE that is possibly, probably or definitely related to the IP.

### 271 **Phase 2A secondary endpoints**

272 Secondary safety and tolerability endpoints for phase 2A include: 1) number of  
273 participants with AEs/TEAEs and SAEs, 2) number of participant withdrawals from the study,  
274 and 3) number of participants discontinuing IP.

### 275 **Phase 2B primary endpoints**

276 The primary cognitive endpoint is the within-participant change from baseline to 72  
277 weeks compared between active arm and placebo on the ADAS-Cog13 [23, 24]. The primary  
278 functional endpoint is the within-participant change from baseline to 72 weeks compared  
279 between active arm and placebo on the CDR-Sum of Boxes (SB) [25, 26].

## 280 **Phase 2B secondary safety and tolerability endpoints**

281 Secondary safety and tolerability endpoints for phase 2B include: 1) number of  
282 participants with AEs/TEAEs and SAEs 2) number of participant withdrawals from the study,  
283 and 3) number of participants discontinuing IP.

## 284 **Phase 2B secondary PK endpoints**

285 Secondary PK endpoints for phase 2B include mean and median levels of: 1) thiamine  
286 (nmol/L), 2) thiamine diphosphate (ThDP) (nmol/L), 3) thiamine monophosphate (ThMP)  
287 (nmol/L) [27], and 4) erythrocyte transketolase activity (U/g haemoglobin (U/gHb)) [28, 29].  
288 Measures of ThDP, ThMP, and erythrocyte transketolase activity will be provided as blood  
289 markers of efficacy of drug delivery. These measurements will be conducted on whole and red  
290 blood cells in samples collected at baseline, week 8, and week 72.

## 291 **Phase 2B secondary efficacy endpoints**

292 Additional efficacy endpoints of benfotiamine will be assessed by within-participant  
293 change from baseline to week 72 between active arm and placebo on the following: 1) the  
294 Alzheimer's Disease Cooperative Study – Activities of Daily Living Scale for use in Mild  
295 Cognitive Impairment (ADCS-ADL-MCI) [30] to evaluate preservation or potential  
296 improvement in everyday activities of daily living, and 2) the MoCA [31] to evaluate  
297 preservation or potential improvement in cognitive function.

## 298 **Phase 2B exploratory endpoints**

299 Exploratory endpoints in phase 2B include within-participant longitudinal change  
300 between active arm and placebo in: 1) cranial MRI volumetric measures of hippocampal, whole  
301 brain, and ventricles, as well as regional cortical thickness, 2) scores on the Neuropsychiatric  
302 Inventory (NPI) [32], 3) scores on neuropsychological test measures administered remotely and  
303 in-person, 4) ADAS-Cog-Exec [33] scores, 5) levels of plasma biomarkers A $\beta$ 42/A $\beta$ 40 ratio, p-  
304 tau217/np-tau217 ratio, p-tau217, total tau, p-tau 231, NfL and GFAP, 6) AGE levels measured  
305 in plasma as an exploratory endpoint of PD, and 7) PK (plasma thiamine, thiamine esters in  
306 whole blood including ThDP and ThMP, and erythrocyte transketolase activity) relationships to  
307 PD biomarkers (AGE) and clinical outcome measures.

308 AGE levels will be measured on plasma samples and four AGE by mass spectrometry  
309 (N(6)-carboxymethyl-lysine (CML), pentosidine, N(6)-carboxymethyl-lysine (CEL),  
310 methylglyoxal-derived hydroimidazolone) will be quantified to measure all specific modes of  
311 action of benfotiamine.

312 Neuropsychological measures administered in-person include the Boston Naming Test  
313 (30-item) [34], the Trail Making Test (Parts A and B) [35], and WAIS-R Digit Symbol  
314 Substitution [36]. Neuropsychological measures administered remotely (via video-call) include  
315 Immediate and Delayed Recall from the Rey Auditory Verbal Learning Test [37], Number Span  
316 Forward and Backward [38], Category Fluency [39] and Letter Fluency [39]. Remote measures  
317 will be administered over videoconference-call within 10 days after each in-person visit  
318 (baseline, week 24, week 48, and week 72). Participants will use their own interactive video  
319 capable devices for the remote assessments, although study-provided devices will be available,  
320 as needed.

## 321 **Power calculation and sample size**

322 Table 3 shows that with a total sample size of  $n=406$  (203/arm), a 20% dropout rate, and  
323 a 5% drop-in rate from the placebo arm to active treatment, the trial will be powered at 80%  
324 overall (90% on each endpoint separately) to detect a difference between arms, corresponding to  
325 a Cohen's  $d$  effect size of 0.38 which represents a small to moderate effect size. This would be a  
326 reasonable and clinically relevant difference between arms on each co-primary endpoint, and  
327 would be commensurate to the 35% to 40% amelioration of decline seen in the placebo arm of  
328 the recently completed phase 2 trial of donanemab in patients with early AD [40], and would  
329 correspond to an absolute difference between arms on the CDR-SB of 0.7 points (assumed SD =  
330 1.74) and of 1.7 points (assumed SD = 4.35) on the ADAS-Cog13.

331  
332 **Table 3. Sample sizes which achieve 90% power for given effect sizes (Cohen's  $D$ ;**  
333 **difference between the 2 arms), assuming 20% dropout and assuming drop-in rates of 5%**  
334 **and 10%**

drop-in rate	effect size	n / arm
5%	0.35	239
<b>5%</b>	<b>0.38</b>	<b>203</b>
5%	0.40	183
10%	0.35	266
10%	0.38	226
10%	0.40	204

335

## 336 **Statistical analyses**

### 337 **Phase 2A**

338 When criteria have been reached to end phase 2A, the unblinded safety biostatistician  
339 will alert the PIs (HHF, JAL, GEG) that the database is to be frozen. An unblinded safety report



340 will be provided to the Data Safety Monitoring Board (DSMB). The phase 2A primary analysis  
341 will compare the rate of TEs between the 1200 mg/day arm and the placebo arm. The analysis  
342 will test whether the rate of TEs is unacceptably high in this high-dose arm compared to placebo,  
343 using a formal one-sided hypothesis test of equal rates, against the one-sided alternative that the  
344 high dose arm TE rate is greater than the placebo arm TE rate. The conditional one-sided test of  
345 Przyborowski and Wilenski [41] will be used, at 5% significance level.

346 Additional phase 2A safety analyses will involve computing an exact upper-one sided  
347 95% confidence interval for the TE rate in each arm. Safety and tolerability data and  
348 demographic data will be summarized in a tabular and/or graphical format for each treatment  
349 group. The incidence of all laboratory test abnormalities and median changes from baseline will  
350 be tabulated by treatment regimen and time point. The safety population (i.e., enrolled and  
351 randomized participants who received at least 1 dose of blinded study therapy) will be used for  
352 these analyses.

## 353 **Phase 2B**

354 The primary analyses will be performed on the modified intent to treat (mITT) population  
355 which includes all randomized participants who took at least one dose of the study medication,  
356 have a baseline assessment of the co-primary efficacy endpoints, and have at least one efficacy  
357 evaluation following baseline. The primary analysis will be the same for each co-primary  
358 endpoint (CDR-SB and ADAS-Cog13) and will test within subject change in the measure as the  
359 outcome in a mixed effects repeated measures model using all available outcomes in the mITT  
360 population with no imputation for missing data. Fixed effects in the model will be *APOE* status,  
361 baseline value of the outcome measure, baseline by visit-week interaction term, treatment group,  
362 visit-week, and visit-week by treatment group interaction. The approach will be maximum

363 likelihood. Visit will be treated as a categorical variable. The covariance structure will be  
364 specified as follows: the random effects will include site and subject. The within-subject  
365 covariance will be unstructured. If needed, sites will be pooled (in order of enrollment, starting  
366 from minimum enrollment) so that there is a minimum of 5 participants per site. If the model  
367 fails to converge at the default setting for the software used, then site will be changed to a fixed  
368 effect, and if this model does not converge, site will be removed from the model. If the model  
369 does not converge, the following structures for the within subject covariance will be fit,  
370 sequentially, until the structure is found that results in convergence of the model: Huynh-Feldt,  
371 Toeplitz, Autoregressive (1), and Compound Symmetry. A sandwich estimator will be utilized to  
372 estimate the variance estimates, and degrees of freedom will be calculated using the between-  
373 within method. The primary endpoint will be tested using model-adjusted least squares means at  
374 the week 72 visit. Point estimates, standard errors, two-sided 95% confidence intervals, and p-  
375 values will be presented.

376       Mean changes in the secondary endpoints from baseline to week 72 will be compared  
377 between arms using the analysis strategy outlined above. To control alpha over the primary and  
378 all secondary endpoints, an overall hierarchical gatekeeper strategy will be used, similar to the  
379 primary analysis. First, if the primary analysis is not significant, then the secondary endpoints  
380 will not be formally tested, and will be presented using exploratory summary statistics only  
381 (means and uncorrected 95% confidence intervals by arm and for the difference between arms).  
382 No claims of statistical significance will be made. However, if the primary analysis is significant,  
383 the secondary endpoints will be tested in the listed order in hierarchical manner, each using an  
384 alpha of 5%. Once a secondary endpoint has failed to attain the prespecified 5% significance  
385 level, the remaining secondary endpoints will be presented as exploratory only. This strategy will

386 maintain the overall familywise significance level for the primary and all secondary endpoints at  
387 5%. Exploratory analyses will be detailed in the statistical analysis plan, and will generally be  
388 similar to the primary and secondary analyses.

389 Safety and tolerability data as well as demographic data for the safety population will be  
390 summarized in tabular and/or graphical format for each treatment group. The incidence of all  
391 laboratory test abnormalities and the median changes from baseline will be tabulated by  
392 treatment regimen and time point.

### 393 **Data safety monitoring board**

394 The DSMB will provide safety oversight of the trial. It is independent from the ADCS  
395 and reports to the National Institute on Aging (NIA) through its project scientist. The DSMB  
396 includes a chair and 4 other experts in the field who have the appropriate background for these  
397 responsibilities and have been approved by the NIA. Other members may be added depending on  
398 the needs of the trial. The DSMB will meet quarterly and on an ad-hoc basis in the face of any  
399 important safety matters that may arise, and will provide recommendations following each  
400 meeting. The final recommendation on dose to select at the end of phase 2A for use in phase 2B  
401 will be made by the DSMB. The DSMB will have the authority to recommend that the study be  
402 halted or discontinued.

### 403 **Early discontinuation**

404 The entire study may be otherwise discontinued at the discretion of the ADCS or the  
405 study PIs (GEG, JAL, HHF) for administrative or other reasons. Participants are free to withdraw  
406 from study participation at any time, for any reason, and without prejudice. Discontinuation of  
407 study treatment and/or the participation of an individual patient can occur in the following  
408 circumstances: 1) withdrawal of informed consent by the participant or legally authorized

409 representative (LAR), 2) treatment with a non-permitted concomitant medication, 3) AE or other  
410 significant medical condition which, in the opinion of the Investigator, render it necessary to  
411 discontinue study drug, 4) medical emergency that necessitates unblinding the participant's  
412 treatment assignment, 5) any other occurrence that, in the PIs opinion, makes continued  
413 participation contrary to the participant's best interest, or 6) movement of the participant into a  
414 long-term care nursing facility. Participants who discontinue study treatment for any reason will  
415 have the opportunity to continue on the protocol to the end of the study with their ongoing  
416 consent.

## 417 **Monitoring & quality control**

418 During the study each site will be monitored at regular intervals by an ADCS clinical  
419 research monitor through a combination of on-site visits and remote monitoring procedures. The  
420 monitoring visits will be conducted according to the applicable International Conference on  
421 Harmonization (ICH) and Good Clinical Practice (GCP) guidelines to ensure protocol adherence,  
422 quality of data, drug accountability, compliance with regulatory requirements, and continued  
423 adequacy of the investigation site and its facilities. Documentation of all quality control  
424 procedures will be outlined in the Data Management Plan. Edit checks and listings will be run  
425 and used in conjunction with electronic case report form pages to support clinical review of the  
426 data.

## 427 **Ethics**

428 Review and approval of the protocol and the associated informed consent documents and  
429 recruitment materials was conducted by the central Institutional Review Board (IRB) Advarra.  
430 Approval from the central IRB will be obtained for all protocol amendments and changes to the

431 informed consent document when they are warranted. The site investigator will notify the central  
432 IRB of deviations from the protocol or SAEs occurring at the site.

433 No study-specific procedure will be undertaken on any individual patient until that  
434 patient or their LAR has given written informed consent to take part in the study. The study  
435 partner must also participate in the consenting process. Participant confidentiality is strictly held  
436 in trust by the participating investigators, research staff, and the sponsoring institution and their  
437 agents.

## 438 **Trial Status**

439 Recruitment for this study began March 22, 2024 and is currently ongoing.

## 440 **Dissemination plan**

441 Study results will be published in accordance with the 2010 Consolidated Standards of  
442 Reporting Trials (CONSORT) guidelines. As there are expected to be too few participants at  
443 each site for an individual site's results to be statistically valid, the results of this study will be  
444 disclosed or published only in combined form based upon the statistical analysis coordinated and  
445 performed by the ADCS. Results will be posted on [clinicaltrials.gov](https://clinicaltrials.gov) in accordance with  
446 requirements.

## 447 **Discussion**

448 There is an urgent need to accelerate and diversify therapeutic possibilities for patients  
449 with AD [8]. Benfotiamine provides an important novel therapeutic direction in AD as it  
450 addresses and treats a well-characterized tissue thiamine action deficiency and related changes in  
451 glucose metabolism as well as post-translational modifications including those promoting plaque  
452 [2] and tangle formation [3], neuroinflammation [4, 5], neurodegeneration [6], and AGE [7].  
453 Benfotiamine has potential to achieve POC, with the possibility of additive or synergistic effects

454 to other current therapeutic approaches, addressing the US National Alzheimer's Project Act  
455 (NAPA) goal of combining targets [8]. The preliminary results of a pilot study provide proof of  
456 principle that justify testing the efficacy of benfotiamine in a larger RCT to investigate its safety,  
457 tolerability, and efficacy in early AD [6, 18].

458         The BenfoTeam trial is deploying an innovative seamless phase 2A-2B design to achieve  
459 POC. This is a double-blind, placebo-controlled RCT of 72-weeks of benfotiamine in early AD  
460 with a randomized sample of 406 participants. It includes an adaptive dose decision rule that  
461 optimizes exposure to the highest and best-tolerated dose. An additional innovation is the use of  
462 plasma-based amyloid and p-tau biomarker tests for inclusion, which provides an important  
463 contribution by shifting away from invasive testing using lumbar puncture or expensive PET  
464 scanning that entails significant radiation exposure. This phase 2A-2B trial is powered to provide  
465 evidence of clinically important benefit and, if positive, it will further validate our approach of  
466 deploying seamless designs with adaptive dose finding, and will provide measures and effect  
467 sizes that can become new benchmarks.

468         Results from the BenfoTeam trial are expected to identify the highest well-tolerated dose  
469 of benfotiamine that has an acceptable safety profile. Measurable PK and PD biomarkers and a  
470 constellation of downstream plasma AD and neurodegenerative biomarkers ensure that the trial  
471 will be able to test the sufficiency of target engagement and dose while evaluating longer term  
472 efficacy and safety. In addition, the sample size is well powered to determine if benfotiamine  
473 will benefit cognition and everyday function in individuals with early AD.

## 474 **Authors Contributions**

475 **Conceptualization:** Howard H. Feldman, Gary E. Gibson, José A. Luchsinger.

476 **Project Directors/Principal Investigators:** Howard H. Feldman, Gary E. Gibson, José A.

477 Luchsinger.

478 **Funding Acquisition:** Howard H. Feldman, Gary E. Gibson [contact principal investigator],

479 José A. Luchsinger.

480 **Methodology:** Howard H. Feldman, Gary E. Gibson, José A. Luchsinger, Karen Messer, Steven

481 D. Edland, Diane M. Jacobs, David P. Salmon, Sarah A. Flowers, Kerry S. Jones, Albert

482 Koulman, Philip B. Verghese, Venky Venkatesh, Kevin Yarasheski, Henrik Zetterberg.

483 **Project Administration:** Carolyn Revta.

484 **Writing – Original Draft Preparation:** Howard H. Feldman, January Durant, Jody-Lynn Lupo.

485 **Writing – Review & Editing:** Howard H. Feldman, Gary E. Gibson, José A. Luchsinger,

486 Gabriel C. Léger, Curtis Taylor, Diane M. Jacobs, David P. Salmon, Karen Messer, Steven D.

487 Edland, Carolyn Revta, Sarah A. Flowers, Kerry S. Jones, Albert Koulman, Philip B. Verghese,

488 Venky Venkatesh, Kevin Yarasheski, Henrik Zetterberg, January Durant, Jody-Lynn Lupo.

## 489 **Acknowledgments**

490

491 The members of the ADCS BenfoTeam Study Group are as follows:

492

493 **ADCS:** Department of Neurosciences, Alzheimer's Disease Cooperative Study, University of

494 California, San Diego, CA, USA.

495 **ADCS Co-Directors:** Howard H. Feldman, Judy Pa.

496 **Project Directors:** Gary E. Gibson (contact PI), José A. Luchsinger, Howard H. Feldman.

497 **Executive Operations:** Carolyn Revta.

498 **Clinical Operations:** Savannah Aries, Briana Askew\*, Kemi Badru\*, Veronica Fernandez,  
499 Nisha Johal\*, Tamesha Lucas, Bryce Truver, Erika Velazco.

500 **Clinical Monitoring:** R. Michelle Brill, Laura Cole, Edward Fox, Ben Germain, Don Guterwill,  
501 Bailey Hoffman, Tiffany Jones, Janet Kastelan, Ike Monye\*, Susan Mroz, Gerald Rivera\*,  
502 Rebecca Ryan-Jones\*, Vicky Syed\*, Kheshini De Zoysa.

503 **Regulatory/Quality Management:** Pat Chinwattana, Lori Houghtaling, Roxana Phillips, Teresa  
504 Ruiz, Rick Seghers.

505 **Data Management:** Susan Castellino\*, Sneha Jasti, Jim Krooskos, Andrew MacKelfresh,  
506 Keerthi Vemuri, Zel Zorin.

507 **Medical Safety:** Gabriel Leger, Alessandra Pol, Curtis Taylor.

508 **Instruments:** Diane M. Jacobs, David P. Salmon.

509 **Recruitment:** Daniel Bennett, Andrea LaCroix, Genevieve Matthews, Donna Tan.

510 **Imaging:** James Brewer, Nichol Ferng, Robin Jennings.

511 **Statistics:** Steven D. Edland, Shelia Jin, Karen Messer, Jing Zhang.

512 **Special Projects/Medical Writing:** January Durant, Jody-Lynn Lupo.

513 **Biomarker/Lab Studies:** Sarah A. Flowers, University of Virginia, Charlottesville, Virginia,  
514 United States of America; Kerry S. Jones, Damon A. Parkington, Sarah R. Meadows and Albert  
515 Koulman, University of Cambridge, Cambridge, United Kingdom; Kevin Yarasheski, Philip B.  
516 Verghese, and Venky Venkatesh, C<sub>2</sub>N Diagnostics, St. Louis, Missouri, United States of America;  
517 Henrik Zetterberg, Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden.

518 \*no longer active at ADCS or with this project



## 519 **Supporting Information**

520 S1 File. **Statistical Methods: Transition from Phase 2A to Phase 2B**

521 S2 File. **Data sharing statement**

522 S3 File. **The protocol approved by the ethics committee**

523 S4 File. **Model consent form**

524 S1 Checklist. **SPIRIT 2013 checklist**

## 525 **References**

- 526 1. Alzheimer's Association, et al., *2017 Alzheimer's disease facts and figures*. 2017,  
527 Alzheimer's Dementia, 2017. **13**(4): p. 325-373.
- 528 2. Yang, Y., et al., *Succinylation Links Metabolic Reductions to Amyloid and Tau*  
529 *Pathology*. 2019, bioRxiv.
- 530 3. Tapias, V., et al., *Benfotiamine treatment activates the Nrf2/ARE pathway and is*  
531 *neuroprotective in a transgenic mouse model of tauopathy*. *Hum Mol Genet*, 2018.  
532 **27**(16): p. 2874-2892.
- 533 4. Anandam, K.Y., et al., *Proinflammatory cytokines inhibit thiamin uptake by human and*  
534 *mouse pancreatic acinar cells: involvement of transcriptional mechanism(s)*. *Am J*  
535 *Physiol Gastrointest Liver Physiol*, 2021. **320**(1): p. G108-G116.
- 536 5. He, Y., et al., *Glyoxalase system: A systematic review of its biological activity, related-*  
537 *diseases, screening methods and small molecule regulators*. *Biomed Pharmacother*, 2020.  
538 **131**: p. 110663.

- 539 6. Gibson, G.E., et al., *Benfotiamine and Cognitive Decline in Alzheimer's Disease: Results*  
540 *of a Randomized Placebo-Controlled Phase IIa Clinical Trial*. J Alzheimers Dis, 2020.  
541 **78**(3): p. 989-1010.
- 542 7. Chou, P.S., et al., *Effect of Advanced Glycation End Products on the Progression of*  
543 *Alzheimer's Disease*. J Alzheimers Dis, 2019. **72**(1): p. 191-197.
- 544 8. Alkhalaf, A., et al., *Effect of benfotiamine on advanced glycation endproducts and*  
545 *markers of endothelial dysfunction and inflammation in diabetic nephropathy*. PLoS One,  
546 2012. **7**(7): p. e40427.
- 547 9. Depeint, F., et al., *Marginal thiamine deficiency increases oxidative markers in the*  
548 *plasma and selected tissues in F344 rats*. Nutrition Research, 2007. **27**(11): p. 698-704.
- 549 10. Victor, M., R.D. Adams, and G.H. Collins, *The Wernicke-Korsakoff syndrome. A clinical*  
550 *and pathological study of 245 patients, 82 with post-mortem examinations*. Contemp  
551 Neurol Ser, 1971. **7**: p. 1-206.
- 552 11. Gibson, G.E., et al., *Reduced activities of thiamine-dependent enzymes in the brains and*  
553 *peripheral tissues of patients with Alzheimer's disease*. Arch Neurol, 1988. **45**(8): p. 836-  
554 40.
- 555 12. Gibson, G.E., et al., *Alpha-ketoglutarate dehydrogenase complex-dependent*  
556 *succinylation of proteins in neurons and neuronal cell lines*. J Neurochem, 2015. **134**(1):  
557 p. 86-96.
- 558 13. Bubber, P., et al., *Mitochondrial abnormalities in Alzheimer brain: mechanistic*  
559 *implications*. Ann Neurol, 2005. **57**(5): p. 695-703.
- 560 14. Gibson, G.E., et al., *Vitamin B1 (thiamine) and dementia*. Ann N Y Acad Sci, 2016.  
561 **1367**(1): p. 21-30.

- 562 15. Ramamoorthy, K., et al., *Alzheimer's disease is associated with disruption in thiamin*  
563 *transport physiology: A potential role for neuroinflammation*. *Neurobiol Dis*, 2022. **171**:  
564 p. 105799.
- 565 16. Suzuki, K., et al., *High-dose thiamine prevents brain lesions and prolongs survival of*  
566 *Slc19a3-deficient mice*. *PLOS ONE*, 2017. **12**(6): p. e0180279.
- 567 17. Pan, X., et al., *Powerful beneficial effects of benfotiamine on cognitive impairment and*  
568 *beta-amyloid deposition in amyloid precursor protein/presenilin-1 transgenic mice*.  
569 *Brain*, 2010. **133**(Pt 5): p. 1342-51.
- 570 18. Gibson, G.E., et al., *Pharmacological thiamine levels as a therapeutic approach in*  
571 *Alzheimer's disease*. *Front Med (Lausanne)*, 2022. **9**: p. 1033272.
- 572 19. Albert, M.S., et al., *The diagnosis of mild cognitive impairment due to Alzheimer's*  
573 *disease: recommendations from the National Institute on Aging-Alzheimer's Association*  
574 *workgroups on diagnostic guidelines for Alzheimer's disease*. *Alzheimers Dement*, 2011.  
575 **7**(3): p. 270-9.
- 576 20. McKhann, G.M., et al., *The diagnosis of dementia due to Alzheimer's disease:*  
577 *Recommendations from the National Institute on Aging-Alzheimer's Association*  
578 *workgroups on diagnostic guidelines for Alzheimer's disease*. *Alzheimer's & Dementia*,  
579 2011. **7**(3): p. 263-269.
- 580 21. Rissman, R.A., et al., *Plasma A $\beta$ 42/A $\beta$ 40 and phospho- $\tau$ 217 concentration ratios*  
581 *increase the accuracy of amyloid PET classification in preclinical Alzheimer's disease*.  
582 *Alzheimer's & Dementia*, 2023.
- 583 22. Meyer MR, K.K., Eastwood S, Wentz-Roth TL, Irvin F, Holubasch MS, Venkatesh V,  
584 Fogelman I, Monane M, Hanna L, Rabinovici GD, Siegel BA, Whitmer RA, Apgar C,

- 585 Bateman RJ, Holtzman DM, Irizarry M, Verbel D, Sachdev P, Ito S, Contois J,  
586 Yarasheski KE, Braunstein JB, Verghese PB, West T., *Clinical Validation of the*  
587 *PrecivityAD2™ blood test: A mass spectrometry-based test with algorithm combining*  
588 *%p-tau217 and Aβ42/40 ratio to identify presence of brain amyloid. Alzheimer's*  
589 *Dement*, 2024. **in press**.
- 590 23. Rosen, W.G., R.C. Mohs, and K.L. Davis, *A new rating scale for Alzheimer's disease.*  
591 *Am J Psychiatry*, 1984. **141**(11): p. 1356-64.
- 592 24. Mohs, R.C., et al., *Development of cognitive instruments for use in clinical trials of*  
593 *antidementia drugs: additions to the Alzheimer's Disease Assessment Scale that broaden*  
594 *its scope. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord,*  
595 *1997. 11 Suppl 2: p. S13-21.*
- 596 25. O'Bryant, S.E., et al., *Validation of the new interpretive guidelines for the clinical*  
597 *dementia rating scale sum of boxes score in the national Alzheimer's coordinating center*  
598 *database. Arch Neurol*, 2010. **67**(6): p. 746-9.
- 599 26. O'Bryant, S.E., et al., *Staging dementia using Clinical Dementia Rating Scale Sum of*  
600 *Boxes scores: a Texas Alzheimer's research consortium study. Arch Neurol*, 2008. **65**(8):  
601 p. 1091-5.
- 602 27. Gallant, J., et al., *Low-dose thiamine supplementation of lactating Cambodian mothers*  
603 *improves human milk thiamine concentrations: a randomized controlled trial. Am J Clin*  
604 *Nutr*, 2021.
- 605 28. Jones, K.S., et al., *Erythrocyte transketolase activity coefficient (ETKAC) assay protocol*  
606 *for the assessment of thiamine status. Annals of the New York Academy of Sciences,*  
607 *2021. 1498*(1): p. 77-84.

- 608 29. Jones, K.S., et al., *Protocol and application of basal erythrocyte transketolase activity to*  
609 *improve assessment of thiamine status*. *Annals of the New York Academy of Sciences*,  
610 2023. **1521**(1): p. 104-111.
- 611 30. Galasko, D., et al., *An inventory to assess activities of daily living for clinical trials in*  
612 *Alzheimer's disease. The Alzheimer's Disease Cooperative Study*. *Alzheimer Dis Assoc*  
613 *Disord*, 1997. **11 Suppl 2**: p. S33-9.
- 614 31. Nasreddine, Z.S., et al., *The Montreal Cognitive Assessment, MoCA: a brief screening*  
615 *tool for mild cognitive impairment*. *J Am Geriatr Soc*, 2005. **53**(4): p. 695-9.
- 616 32. Cummings, J.L., *The Neuropsychiatric Inventory: assessing psychopathology in dementia*  
617 *patients*. *Neurology*, 1997. **48**(5 Suppl 6): p. S10-16.
- 618 33. Jacobs, D.M., et al., *Development of a novel cognitive composite outcome to assess*  
619 *therapeutic effects of exercise in the EXERT trial for adults with MCI: The ADAS-Cog-*  
620 *Exec*. *Alzheimers Dement (N Y)*, 2020. **6**(1): p. e12059.
- 621 34. Kaplan, E., H. Goodglass, and S. Weintraub, *The Boston Naming Test*. Philadelphia: Lea  
622 and Febiger, 1983.
- 623 35. Office, A.G.s., *Manual of Directions and Scoring*. In: *Army Individual Test Battery*.  
624 Washington DC: War Department, 1944.
- 625 36. Wechsler, D., *Wechsler Adult Intelligence Scale-Revised. ; 1981*. The Psychological  
626 Corporation, 1981.
- 627 37. Rey, A., *L'examen Clinique en psychologie*. Paris: Presses Universitaires de France,  
628 1964.
- 629 38. Besser, L., et al., *Version 3 of the National Alzheimer's Coordinating Center's Uniform*  
630 *Data Set*. *Alzheimer Dis Assoc Disord*, 2018.

- 631 39. Morris, J.C., et al., *The Consortium to Establish a Registry for Alzheimer's Disease*  
632 *(CERAD). Part I. Clinical and neuropsychological assessment of Alzheimer's disease.*  
633 *Neurology*, 1989. **39**(9): p. 1159-65.
- 634 40. Mintun, M.A., et al., *Donanemab in Early Alzheimer's Disease*. *N Engl J Med*, 2021.  
635 **384**(18): p. 1691-1704.
- 636 41. Przyborowski, J. and H. Wilenski, *Homogeneity of results in testing samples from*  
637 *Poisson series: With an application to testing clover seed for dodder*. *Biometrika*, 1940.  
638 **31**(3-4): p. 313-323.
- 639  
640

**Figure 1. Schedule of enrollment, interventions, and assessments**

	Enrollment	Allocation	STUDY PERIOD									
			Post-allocation								End	
Visit Number	1	2	3	4	5	6	7	8	9	10	11	
TIMEPOINT	Screening	Baseline	Wk 4	Wk 8	Wk 12	Wk 24	Wk 36	Wk 48	Wk 60	Wk 72	Wk 76	
<b>ENROLLMENT:</b>												
Informed consent	X											
Eligibility review	X	X										
Allocation		X										
<b>INTERVENTIONS:</b>												
Benfotiamine 1200mg/day*		←	—————→									
Benfotiamine 600mg/day*		←	—————→									
Placebo		←	—————→									
* Phase 2A of the trial will randomize participants 1:1:1 to 1200 mg/day benfotiamine, 600 mg/day benfotiamine or placebo. At the end of phase 2A, only the highest safe and well-tolerated dose of benfotiamine (1200mg/day or 600mg/day) will be carried forward to phase 2B.												
<b>ASSESSMENTS:</b>												
CDR	X					X		X		X		
ADAS-Cog13		X				X		X		X		
ADCS-ADL-MCI		X				X		X		X		

Visit Number	STUDY PERIOD										
	Enrollment	Allocation	Post-allocation							End	
	1	2	3	4	5	6	7	8	9	10	11
TIMEPOINT	Screening	Baseline	Wk 4	Wk 8	Wk 12	Wk 24	Wk 36	Wk 48	Wk 60	Wk 72	Wk 76
MoCA	X					X		X		X	
Concomitant Medication											
Adverse Events											
12-lead ECG (resting)	X					X				X	
Safety Blood Tests TSH, Hemoglobin Alc, Infectious Disease Serology, Urinalysis											
Blood Sampling for PD: AGE		X		X						X	
Blood Sampling for PK: thiamine, ThDP, ThMP, erythrocyte transketolase activity		X		X						X	
Blood Sampling for PrecivityAD2 test which includes Aβ42/ Aβ40 Ratio, p-tau217/np- tau217(p-tau217 Ratio)	X									X	
Blood Sampling for Biomarkers (total tau, p- tau231, p-tau217, NfL, GFAP)		X								X	





\* Abbreviations: ECG - electrocardiogram, TSH - thyroid stimulating hormone, PK - pharmacokinetics, PD - pharmacodynamics, AGE – advanced glycation end products, ThDP - thiamine diphosphate, ThMP - thiamine monophosphate, NFL - Neurofilament light chain, GFAP - Glial Fibrillary Acidic Protein, A $\beta$  - Beta-amyloid, MRI - Magnetic resonance imaging, CSF - Cerebrospinal fluid, LP – lumbar puncture, CAIGE-AID - CAGE Adapted to Include Drugs, C-SSRS – Columbia - Suicide Severity Rating Scale, MoCA – Montreal Cognitive Assessment, MMSE – Mini Mental State Exam, CDR – Clinical Dementia Rating, ADAS-Cog13 - Alzheimer's Disease Assessment Scale-Cognitive Subscale 13, ADCS-ADL-MCI – Alzheimer's Disease Cooperative Study – Activities of Daily Living Scale for use in Mild Cognitive Impairment, , NPI – Neuropsychiatric Inventory, IP - Investigational Product.

